These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
567 related articles for article (PubMed ID: 26857243)
1. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation. Bae JS; Kim Y; Jeon S; Kim SH; Kim TJ; Lee S; Kim MH; Lim DJ; Lee YS; Jung CK Diagn Pathol; 2016 Feb; 11():21. PubMed ID: 26857243 [TBL] [Abstract][Full Text] [Related]
2. Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population. Lee SE; Hwang TS; Choi YL; Han HS; Kim WS; Jang MH; Kim SK; Yang JH Thyroid; 2016 Jul; 26(7):901-10. PubMed ID: 27184112 [TBL] [Abstract][Full Text] [Related]
3. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas. Onder S; Ozturk Sari S; Yegen G; Sormaz IC; Yilmaz I; Poyrazoglu S; Sanlı Y; Giles Senyurek Y; Kapran Y; Mete O Endocr Pathol; 2016 Jun; 27(2):153-61. PubMed ID: 26951110 [TBL] [Abstract][Full Text] [Related]
4. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. Liu X; Qu S; Liu R; Sheng C; Shi X; Zhu G; Murugan AK; Guan H; Yu H; Wang Y; Sun H; Shan Z; Teng W; Xing M J Clin Endocrinol Metab; 2014 Jun; 99(6):E1130-6. PubMed ID: 24617711 [TBL] [Abstract][Full Text] [Related]
5. BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients. Sun J; Zhang J; Lu J; Gao J; Ren X; Teng L; Duan H; Lin Y; Li X; Zhang B; Liang Z PLoS One; 2016; 11(4):e0153319. PubMed ID: 27064992 [TBL] [Abstract][Full Text] [Related]
6. TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer. Yang X; Li J; Li X; Liang Z; Gao W; Liang J; Cheng S; Lin Y J Nucl Med; 2017 Feb; 58(2):258-265. PubMed ID: 27493271 [TBL] [Abstract][Full Text] [Related]
7. In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF Nasirden A; Saito T; Fukumura Y; Hara K; Akaike K; Kurisaki-Arakawa A; Asahina M; Yamashita A; Tomomasa R; Hayashi T; Arakawa A; Yao T Virchows Arch; 2016 Dec; 469(6):687-696. PubMed ID: 27718012 [TBL] [Abstract][Full Text] [Related]
8. Cytologic, clinicopathologic, and molecular features of papillary thyroid carcinoma with prominent hobnail features: 10 case reports and systematic literature review. Lee YS; Kim Y; Jeon S; Bae JS; Jung SL; Jung CK Int J Clin Exp Pathol; 2015; 8(7):7988-97. PubMed ID: 26339365 [TBL] [Abstract][Full Text] [Related]
9. Camargo Barros-Filho M; Barreto Menezes de Lima L; Bisarro Dos Reis M; Bette Homem de Mello J; Moraes Beltrami C; Lopes Pinto CA; Kowalski LP; Rogatto SR Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30884810 [TBL] [Abstract][Full Text] [Related]
10. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China. Huang M; Yan C; Xiao J; Wang T; Ling R Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059 [TBL] [Abstract][Full Text] [Related]
11. Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases. Bonhomme B; Godbert Y; Perot G; Al Ghuzlan A; Bardet S; Belleannée G; Crinière L; Do Cao C; Fouilloux G; Guyetant S; Kelly A; Leboulleux S; Buffet C; Leteurtre E; Michels JJ; Tissier F; Toubert ME; Wassef M; Pinard C; Hostein I; Soubeyran I Thyroid; 2017 May; 27(5):682-692. PubMed ID: 28351340 [TBL] [Abstract][Full Text] [Related]
12. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population. Qasem E; Murugan AK; Al-Hindi H; Xing M; Almohanna M; Alswailem M; Alzahrani AS Endocr Relat Cancer; 2015 Dec; 22(6):901-8. PubMed ID: 26354077 [TBL] [Abstract][Full Text] [Related]
13. Presence of TERT ± BRAF V600E mutation is not a risk factor for the clinical management of patients with papillary thyroid microcarcinoma. Lee J; Ha EJ; Roh J; Kim HK Surgery; 2021 Sep; 170(3):743-747. PubMed ID: 33952391 [TBL] [Abstract][Full Text] [Related]
14. Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: Promising value of TERT promoter mutations and insignificant role of BRAF mutations-a meta-analysis. Vuong HG; Altibi AM; Duong UN; Ngo HT; Pham TQ; Tran HM; Oishi N; Mochizuki K; Nakazawa T; Hassell L; Katoh R; Kondo T Tumour Biol; 2017 Oct; 39(10):1010428317713913. PubMed ID: 29037127 [TBL] [Abstract][Full Text] [Related]
15. Effects of Coexistent BRAF Moon S; Song YS; Kim YA; Lim JA; Cho SW; Moon JH; Hahn S; Park DJ; Park YJ Thyroid; 2017 May; 27(5):651-660. PubMed ID: 28181854 [TBL] [Abstract][Full Text] [Related]
16. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma. Bournaud C; Descotes F; Decaussin-Petrucci M; Berthiller J; de la Fouchardière C; Giraudet AL; Bertholon-Gregoire M; Robinson P; Lifante JC; Lopez J; Borson-Chazot F Eur J Cancer; 2019 Feb; 108():41-49. PubMed ID: 30648628 [TBL] [Abstract][Full Text] [Related]
17. Association of BRAFV600E mutation with clinicopathological features of papillary thyroid carcinoma: a study on a Chinese population. Liu S; Zhang B; Zhao Y; Chen P; Ji M; Hou P; Shi B Int J Clin Exp Pathol; 2014; 7(10):6922-8. PubMed ID: 25400776 [TBL] [Abstract][Full Text] [Related]
18. [ Yang T; Chen C; Pan NF; Sun LY; Jiang XL; Li JN; Tang Y; Jiang Y Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 Dec; 50(6):919-924. PubMed ID: 31880125 [TBL] [Abstract][Full Text] [Related]
19. Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy. Li J; Liang J; Zhao T; Lin Y Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1034-9. PubMed ID: 26780618 [TBL] [Abstract][Full Text] [Related]
20. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients. Jin L; Chen E; Dong S; Cai Y; Zhang X; Zhou Y; Zeng R; Yang F; Pan C; Liu Y; Wu W; Xing M; Zhang X; Wang O Oncotarget; 2016 Apr; 7(14):18346-55. PubMed ID: 26943032 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]